{"title":"优化人类胰岛素调节脂肪分解的措施。","authors":"Yilin Song, Kelli A Lytle, Michael D Jensen","doi":"10.1152/ajpendo.00078.2025","DOIUrl":null,"url":null,"abstract":"<p><p>The goals of these studies were to test for errors in measuring the insulin concentration resulting in 50% suppression from baseline free fatty acid palmitate rate of appearance (FFA<sub>palmitate</sub> IC<sub>50</sub>) when measured with a two-step, euglycemic, hyperinsulinemic clamp (EHC). We also determined the reproducibility of FFA<sub>palmitate</sub> IC<sub>50</sub> in weight-stable adults and assessed the magnitude of the change in FFA<sub>palmitate</sub> IC<sub>50</sub> in response to weight loss. To accomplish this, we analyzed data from 46 studies of 27 volunteers enrolled in two ongoing clinical research studies that included weight loss by lifestyle intervention or bariatric surgery. FFA palmitate kinetics were measured using an intravenous infusion of [U-<sup>13</sup>C]palmitate under basal (fasting) and a two-step EHC. For 40 of 46 studies, calculating FFA<sub>palmitate</sub> IC<sub>50</sub> using data from both steps of a EHC overestimated FFA<sub>palmitate</sub> IC<sub>50</sub> compared with the first (low) dose, which suppressed palmitate Ra by > 50%. FFA<sub>palmitate</sub> IC<sub>50</sub> did not change and was reproducible after 4 mo (<i>r</i> = 0.70, <i>P</i> = 0.02) for 10 weight-stable volunteers. Weight loss by either intervention reduced FFA<sub>palmitate</sub> IC<sub>50</sub>, and the reduction was correlated with fat loss and change in adipocyte size. We conclude that, although a two-step EHC (with an initial low dose) allows accurate assessment of FFA<sub>palmitate</sub> IC<sub>50</sub>, careful scrutiny of each set of study data is needed. These data will improve the ability of investigators to design studies that can detect small but important differences or changes in adipose tissue insulin action. NCT clinical trial numbers NCT03866408 and NCT03868592.<b>NEW & NOTEWORTHY</b> Accurate measures of insulin regulation of adipose tissue lipolysis (free fatty acid release rates) in humans can be accomplished using a two-step, hyperinsulinemic clamp experimental design, but careful scrutiny of the data is needed. The FFA<sub>palmitate</sub> IC<sub>50</sub> measure is reproducible in weight-stable adults and responds to treatment interventions in a quantitative manner.</p>","PeriodicalId":7594,"journal":{"name":"American journal of physiology. Endocrinology and metabolism","volume":" ","pages":"E59-E66"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180127/pdf/","citationCount":"0","resultStr":"{\"title\":\"Optimizing measures of insulin-regulated lipolysis in humans.\",\"authors\":\"Yilin Song, Kelli A Lytle, Michael D Jensen\",\"doi\":\"10.1152/ajpendo.00078.2025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The goals of these studies were to test for errors in measuring the insulin concentration resulting in 50% suppression from baseline free fatty acid palmitate rate of appearance (FFA<sub>palmitate</sub> IC<sub>50</sub>) when measured with a two-step, euglycemic, hyperinsulinemic clamp (EHC). We also determined the reproducibility of FFA<sub>palmitate</sub> IC<sub>50</sub> in weight-stable adults and assessed the magnitude of the change in FFA<sub>palmitate</sub> IC<sub>50</sub> in response to weight loss. To accomplish this, we analyzed data from 46 studies of 27 volunteers enrolled in two ongoing clinical research studies that included weight loss by lifestyle intervention or bariatric surgery. FFA palmitate kinetics were measured using an intravenous infusion of [U-<sup>13</sup>C]palmitate under basal (fasting) and a two-step EHC. For 40 of 46 studies, calculating FFA<sub>palmitate</sub> IC<sub>50</sub> using data from both steps of a EHC overestimated FFA<sub>palmitate</sub> IC<sub>50</sub> compared with the first (low) dose, which suppressed palmitate Ra by > 50%. FFA<sub>palmitate</sub> IC<sub>50</sub> did not change and was reproducible after 4 mo (<i>r</i> = 0.70, <i>P</i> = 0.02) for 10 weight-stable volunteers. Weight loss by either intervention reduced FFA<sub>palmitate</sub> IC<sub>50</sub>, and the reduction was correlated with fat loss and change in adipocyte size. We conclude that, although a two-step EHC (with an initial low dose) allows accurate assessment of FFA<sub>palmitate</sub> IC<sub>50</sub>, careful scrutiny of each set of study data is needed. These data will improve the ability of investigators to design studies that can detect small but important differences or changes in adipose tissue insulin action. NCT clinical trial numbers NCT03866408 and NCT03868592.<b>NEW & NOTEWORTHY</b> Accurate measures of insulin regulation of adipose tissue lipolysis (free fatty acid release rates) in humans can be accomplished using a two-step, hyperinsulinemic clamp experimental design, but careful scrutiny of the data is needed. The FFA<sub>palmitate</sub> IC<sub>50</sub> measure is reproducible in weight-stable adults and responds to treatment interventions in a quantitative manner.</p>\",\"PeriodicalId\":7594,\"journal\":{\"name\":\"American journal of physiology. Endocrinology and metabolism\",\"volume\":\" \",\"pages\":\"E59-E66\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180127/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of physiology. Endocrinology and metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1152/ajpendo.00078.2025\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of physiology. Endocrinology and metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1152/ajpendo.00078.2025","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Optimizing measures of insulin-regulated lipolysis in humans.
The goals of these studies were to test for errors in measuring the insulin concentration resulting in 50% suppression from baseline free fatty acid palmitate rate of appearance (FFApalmitate IC50) when measured with a two-step, euglycemic, hyperinsulinemic clamp (EHC). We also determined the reproducibility of FFApalmitate IC50 in weight-stable adults and assessed the magnitude of the change in FFApalmitate IC50 in response to weight loss. To accomplish this, we analyzed data from 46 studies of 27 volunteers enrolled in two ongoing clinical research studies that included weight loss by lifestyle intervention or bariatric surgery. FFA palmitate kinetics were measured using an intravenous infusion of [U-13C]palmitate under basal (fasting) and a two-step EHC. For 40 of 46 studies, calculating FFApalmitate IC50 using data from both steps of a EHC overestimated FFApalmitate IC50 compared with the first (low) dose, which suppressed palmitate Ra by > 50%. FFApalmitate IC50 did not change and was reproducible after 4 mo (r = 0.70, P = 0.02) for 10 weight-stable volunteers. Weight loss by either intervention reduced FFApalmitate IC50, and the reduction was correlated with fat loss and change in adipocyte size. We conclude that, although a two-step EHC (with an initial low dose) allows accurate assessment of FFApalmitate IC50, careful scrutiny of each set of study data is needed. These data will improve the ability of investigators to design studies that can detect small but important differences or changes in adipose tissue insulin action. NCT clinical trial numbers NCT03866408 and NCT03868592.NEW & NOTEWORTHY Accurate measures of insulin regulation of adipose tissue lipolysis (free fatty acid release rates) in humans can be accomplished using a two-step, hyperinsulinemic clamp experimental design, but careful scrutiny of the data is needed. The FFApalmitate IC50 measure is reproducible in weight-stable adults and responds to treatment interventions in a quantitative manner.
期刊介绍:
The American Journal of Physiology-Endocrinology and Metabolism publishes original, mechanistic studies on the physiology of endocrine and metabolic systems. Physiological, cellular, and molecular studies in whole animals or humans will be considered. Specific themes include, but are not limited to, mechanisms of hormone and growth factor action; hormonal and nutritional regulation of metabolism, inflammation, microbiome and energy balance; integrative organ cross talk; paracrine and autocrine control of endocrine cells; function and activation of hormone receptors; endocrine or metabolic control of channels, transporters, and membrane function; temporal analysis of hormone secretion and metabolism; and mathematical/kinetic modeling of metabolism. Novel molecular, immunological, or biophysical studies of hormone action are also welcome.